Sign in
ODTC Stock Price, Chart, Stats & News
Odonate Therapeutics, Inc.
Save
Odonate Therapeutics, Inc. (ODTC) does not currently pay a dividend.
8.05B
Market cap
0.52x
Current P/E
–
Forward P/E
ODTC chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Odonate Therapeutics, Inc., a pharmaceutical company established in 2013 and headquartered in New York, New York, is dedicated to creating treatments for cancer. Its primary therapeutic in development is tesetaxel, an orally administered chemotherapy drug. This agent is currently undergoing a Phase III clinical study for its application in patients suffering from metastatic breast cancer.
Similar securities
Based on sector and market capitalization
Report issue